1. Home
  2. SLI vs CDNA Comparison

SLI vs CDNA Comparison

Compare SLI & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Standard Lithium Ltd.

SLI

Standard Lithium Ltd.

HOLD

Current Price

$3.84

Market Cap

1.0B

Sector

Industrials

ML Signal

HOLD

Logo CareDx Inc.

CDNA

CareDx Inc.

HOLD

Current Price

$20.89

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SLI
CDNA
Founded
1998
1998
Country
Canada
United States
Employees
N/A
N/A
Industry
Major Chemicals
Medical Specialities
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.0B
IPO Year
2011
2007

Fundamental Metrics

Financial Performance
Metric
SLI
CDNA
Price
$3.84
$20.89
Analyst Decision
Strong Buy
Buy
Analyst Count
3
6
Target Price
$5.25
$27.60
AVG Volume (30 Days)
1.7M
704.2K
Earning Date
05-08-2026
04-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$48,324,000.00
Revenue This Year
N/A
$16.01
Revenue Next Year
N/A
$11.31
P/E Ratio
N/A
N/A
Revenue Growth
N/A
18.93
52 Week Low
$1.37
$10.96
52 Week High
$6.40
$23.24

Technical Indicators

Market Signals
Indicator
SLI
CDNA
Relative Strength Index (RSI) 53.21 61.78
Support Level $3.16 $16.63
Resistance Level $4.42 $21.05
Average True Range (ATR) 0.22 1.25
MACD 0.07 0.47
Stochastic Oscillator 70.66 68.49

Price Performance

Historical Comparison
SLI
CDNA

About SLI Standard Lithium Ltd.

Standard Lithium Corp is engaged in the exploration and development of lithium brine properties in the United States. The company is focused on the exploration and development of the Arkansas Lithium Project, which is located in south-central Arkansas. Its other projects comprise the Lanxess Project, and Bristol Dry Lake Project.

About CDNA CareDx Inc.

CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.

Share on Social Networks: